Kappa-opioid receptor ligands

Bibliography

• McCAWLEY EL, HART ER, MARSH DF:The preparation of N-allylnormorphine. J. Am. Chem. Soc. (1941) 63:314–314.
   Google Scholar
• LASAGNE L, BEECHER H: The analgesiceffectiveness of nalorphine and nalorphine-morphine combinations in marl. Pharmacol . Exp. Ther. (1954) 122:356–363.
   Google Scholar
• MARTIN WR: Opioid antagonists. Pharmacol. Rev (1967) 19:463–521.
   PubMed Web of Science ®Google Scholar
• PEARL J, HARRIS LS: Inhibition of writhing by narcotic antagonists. Pharmacol. Exp. Ther. (1966) 154:319–323.
   PubMed Web of Science ®Google Scholar
• LORD JA, WATERFIELD AA, HUGHES J, KOSTERLITZ HW: Endogenous opioid peptides: multiple agonists and receptors. Nature (1977) 267:495–499.
   PubMed Web of Science ®Google Scholar
• MARTIN WR, FRASER HF, GORODETZKY CW, ROSENBERG DE: Studies of the dependence producing potential of the narcotic antagonist 2-cyclopropylmethy1-2'-hydroxy-5,9-dimethy1-6,7-benzmorphan j Pharmacol. Exp. Ther. (1965) 150:426–436.
   PubMed Web of Science ®Google Scholar
• JASINSKI DR, GRIFFITH JD, PEVNICK JS, CLARK SC: Progress report on studies from the clinical pharmacology section of the Addiction Research Center. Proceedings of the 37th Meeting of the Committee on Problems of Drug Dependence. (1975):136–161.
   Google Scholar
• PFEIFFER A, BRANTL V, HERZ A: Psychotomimesis mediated by x-opiate receptors. Science (1986) 233:774–776.
   PubMed Web of Science ®Google Scholar
• REECE PA, SEDMAN AJ, ROSES, WRIGHT DS, DAWKINS R, RAJAGOPALAN R: Diuretic effects, pharmacokinetics, and safety of a new centrally acting x-opioid agonist (CI-977) in humans. J. Cliii. Pharmacol. (1994) 34:1126–1132.
   PubMed Web of Science ®Google Scholar
• CHAPPELL PB, LECKMAN JF, SCAHILL LD, HARDIN MT, ANDERSON G, COHEN DJ: Neuroendocrine and behavioural effects of the selective x-agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. (1993) 47:267–280.
   PubMed Web of Science ®Google Scholar
• PANDE AC, PYKE RE, GREINER M, COOPER SA, BENJAMIN R, PIERCE MW: Analgesic efficacy of the x-receptor agonist, enadoline, in dental surgery pain. Clin. Neuropharmacol. (1996a) 19:92–97.
   PubMed Web of Science ®Google Scholar
• PANDE AC, PYKE RE, GREINER M, WIDEMAN GL, BENJAMIN R, PIERCE MW: Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. OM Neuropharmacol. (1996b) 19:451–456.
   PubMed Web of Science ®Google Scholar
• WALSH SL, STRAIN EC, ABREU ME, BIGELOW GE: Enadoline, a selective x-opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacol. (2001) 157:151–162.
   PubMed Web of Science ®Google Scholar
• CHEN T-Y, GOYAGI T, TOUNG TJK et at. Prolonged opportunity for ischemic neuroprotection with selective x-opioid receptor agonist in rats. Stroke (2004) 35:1180–1185.
   Google Scholar
• MERCADANTE S, ARCURI E: Opioids and renal function. Path (2004) 5:2–19.
   Google Scholar
• KO MCH, LEE H, SONG MS et al: Activation of x-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. Pharmacol. Exp. Ther. (2003) 305:173–179.
   PubMed Web of Science ®Google Scholar
• KUMAGAI H, SARUTA T, MATSUKAWA S, UTSUMI J: Prospects for a novel x-opioid receptor agonist, TRK-820, in uremic pruritus. Basic Clin. Dermatol. (2004) 27:279–286.
   Google Scholar
• MARIN C, BOVE J, BONASTRE M, TOLOSA E: Effect of acute and chronic administration of U50,488, a x-opioid receptor agonist, in 6-0HDA-lesioned rats chronically treated with levodopa. Exp. Neurology (2003) 183:66–73.
   PubMed Web of Science ®Google Scholar
• GHELARDINI C, GALEOTTI N, DI CESARE MANNELLI L, CAPPELLI A, ANZINI M, BARTOLINI A: Antiamnesic effect of the two novel x-opioid agonists, VA-100 and VA-101, in the mouse passive avoidance test. Drug Dev. Res. (2001) 54:12–18.
   Google Scholar
• NEGUS SS, MELLO NK, PORTOGHESE PS, UN CE: Effects of x-opioids on cocaine self-administration by rhesus monkeys. Pharmacol Exp. Ther. (1997) 282:44–55.
   PubMed Web of Science ®Google Scholar
• MELLO NK, NEGUS SS: Effects of x-opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. Pharmacol Exp. Ther. (1998) 286:812–824.
   PubMed Web of Science ®Google Scholar
• GLICK SD, MAISSONEUVE IM, RAUCCI J, ARCHERS: x-Opioid inhibition of morphine and cocaine self-administration in rats. Broth Res. (1995) 681:147–152.
   PubMed Web of Science ®Google Scholar
• BIDLACK JM, COHEN DJ, MCLAUGHLIN JP, LOU R, YE Y, WENTLAND MP: 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan. Pharmacol Exp. Ther. (2002) 302:374–380
   PubMed Web of Science ®Google Scholar
• SUZUKI T, SHIOZAKI Y, MASUKAWA Y, MISAWA M, NAGASE H: The role of µ- and x-opioid receptors in cocaine-induced conditioned place preference. fpn. Pharmacol (1992) 58:435–442.
   Web of Science ®Google Scholar
• TZAFERIS JA, MCGINTY JF: x -Opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum. Mol Brain Res. (2001) 93:27–35.
   PubMedGoogle Scholar
• UKAI M, MIZUTANI M, KAMEYAMA T: Opioid peptides selective for receptor types modulate cocaine-induced behavioural responses in mice. Yakubutsu Seishin Kodo (1994) 14:153–159.
   Google Scholar
• CRAWFORD CA, MCDOUGALL SA, BOLANOS CA, HALLS, BERGER SP: The effects of the x-agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviours and Fos immunoreactivity. Psychopharmacology (1995) 120:392–399.
   PubMed Web of Science ®Google Scholar
• SHIPPENBERG TS, LEFEVOUR A, HEIDBREDER CH: x-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. Pharmacol Exp. Ther (1996) 276:545–554.
   PubMed Web of Science ®Google Scholar
• MORI T, NOMURA M, NAGASE H, SUZUKI T: Effects of newly synthesised x-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology, (2002) 161:17–22.
   Google Scholar
• MELLO NK, NEGUS SS: Interactions between x-opioid agonists and cocaine - preclinical studies. New medications for drug abuse. Ann. NY Acad. Sci. (2000) 909:104–132.
   PubMed Web of Science ®Google Scholar
• COSGROVE KP, CARROLL ME: Effectsof bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: A behavioural economic analysis. Pharmacol Exp. Ther. (2002) 301:993–1002.
   PubMed Web of Science ®Google Scholar
• PRESTON KI, UMBRICHT A, SCHROEDER JR, ABREU M, PICKWORTH WB: Cyclazocine: comparison to hydromorphone and interaction with cocaine. Drug Alc. Depend. (2001) 63\(Supp1.1):S126.
   Google Scholar
• METZGER TG, PATERLINI MG, PORTOGHESE PS, FERGUSON DM: Application of the message-address concept of the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem. Res. (1996) 21:1287–1294.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAN G, PATERLINI MG, LARSON DL, PORTOGHESE PS, FERGUSON DM: Conformational analysis and automated receptor docking of selective arylacetamide-based x-opioid agonists. J. Med. Chem. (1998) 41:4777–4789.
   PubMed Web of Science ®Google Scholar
• HOLZGRABE U, BRANDT W: Mechanismof action of the diazabicyclononanone-type x-agonists. (2003) 46:1383–1389.
   Google Scholar
• SEMPLE G, ANDERSON BM, CHHAJLANI V et al.: 3-Aryl pyridone derivatives. Potent and selective x-opioid receptor agonists. Bioorg. Med. Chem. Lett. (2002) 12:197–200.
   PubMed Web of Science ®Google Scholar
• SEMPLE G, ANDERSON BM, CHHAJLANI V et al.: Synthesis and biological activity of x-opioid receptor agonists. Part 2: Preparation of 3-ary1-2-pyridone analogues generated by solution-and solid-phase parallel synthesis methods. Bioorg. Med. Chem. Lett. (2003) 13:1141–1145.
   Google Scholar
• SHARMA SK, JONES RM, METZGER TG et al.: Transformation of a x-opioid receptor antagonist to a x-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. Med. Chem. (2001) 44: 2073–2079.
   Web of Science ®Google Scholar
• •A further nuance added to the message address concept, with a KOR agonist generated in the GNTI series of KOR antagonists.
   Google Scholar
• DONDIO G, RONZONI S, PETRILLO P: Non-peptide 8-opioid agonists and antagonists. Exp. Opin. Ther. Patents (1997) 7:1075–1098.
   Web of Science ®Google Scholar
• TJOLSEN A, BERGE O-G, HUNSKAAR S, ROSLAND JH, HOLE K: The formalin test: an evaluation of the method. Path (1992) 51:5–17.
   Google Scholar
• WHEELER-ACE TO H, COWAN A: Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacol (1991) 104:35–44.
   Web of Science ®Google Scholar
• KUMAR V, MARELLA MA, CORTES-BURGOS L et al: Arylacetamides as peripherally restricted x-opioid receptor agonists. Bioorg. Med. Chem. Lett. (2000) 10:2567–2570.
   PubMed Web of Science ®Google Scholar
• SHAW JS, CARROLL JA, ALCOC P, MAIN BG: ICI 204448: a x-opioid agonist with limited access to the CNS. Br J. Pharmacol (1989) 96:986–992.
   PubMed Web of Science ®Google Scholar
• KEITA H, KAYSER V, GUILBAUD G: Antinociceptive effect of a x-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI-204448) in a rat model of mononeuropathy. Eur. Pharmacol (1995) 277: 275–280.
   PubMed Web of Science ®Google Scholar
• WENTLAND MP, LOU R, YE Y et al: 8-Carboxamidocyclazocine analogues: Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Bioorg. Med. Chem. Lett. (2001) 11:623–626.
   PubMed Web of Science ®Google Scholar
• WENTLAND MP, YE Y, CIOFFI C et al: Synthesis and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. J. Med. Chem. (2003) 46:838–849.
   PubMed Web of Science ®Google Scholar
• WENTLAND MP, DUAN W, COHEN DJ, BID LACK JM: Selective protection and functionalization of morphine: Synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives. J. Med. Chem. (2000) 43:3558–3565.
   PubMed Web of Science ®Google Scholar
• WENTLAND MP, LOU R, DEHNHARDT CM et al: 3-Carboxamido analogues of morphine and naltrexone: Synthesis and opioid receptor binding properties. Bioorg. Med. Chem. Lett. (2001) 11:1717–1721.
   PubMed Web of Science ®Google Scholar
• BIDLACK JM, COHEN DJ, MCLAUGHLIN JP et al: 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan../. Pharmacol Exp. Ther. (2002) 302:374–380.
   Google Scholar
• NEUMEYER JL, GU X-H, VAN VLIET LA et at Mixed x-agonists and t agonists/ antagonists as potential pharmacotherapeutics for cocaine abuse: Synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg. Med. Chem. Lett. (2001) 11: 2735–2740.
   PubMed Web of Science ®Google Scholar
• ZHANG A, XIONG W BIDLACK JM et al.: 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed lc and p-opioid ligands: Synthesis and biological evaluation of their binding affinity at opioid receptors. J. Med. Chem. (2004) 47:165–174.
   Google Scholar
• PORTOGHESE PS, LIPKOWSKI AW, TAKEMORI AE: Binaltorphimine and nor-binaltorphimine, potent and selective x-opioid receptor antagonists. Lai. Sci. (1987) 40:1287–1292.
   PubMed Web of Science ®Google Scholar
• STEVENS WC JR, JONES RM, SUBRAMANIAN G et al: Potent and selective indolomorphinan antagonists of the x-opioid receptor. J. Med. Chem. (2000) 43:2759–2769.
   PubMedGoogle Scholar
• SCHWYZER R: A short introductory review.Ann. NY Acad. Sci. (1997) 247:3–26.
   Google Scholar
• PORTOGHESE PS: From models to molecules: Opioid receptor dimers, bivalent ligands and selective opioid receptor probes. J. Med. Chem. (2001) 44: 2259–2269.
   PubMed Web of Science ®Google Scholar
• THOMAS JB, ATKINSON RN, ROTHMAN RB et al: Identification of the first trans-(3R,410-dimethyl 4 (3 hydroxyphenyflpiperidine derivative to possess highly potent and selective opioid x-receptor antagonist activity. J. Med. Chem. (2001) 44:2687–2690.
   PubMed Web of Science ®Google Scholar
• •A new message pharmacophore in KOR antagonist design.
   Google Scholar
• THOMAS JB, ATKINSON RN, VINSON NA et al: Identification of (3/0-7-hydroxy-N-((15)-1-{l3R,4A) 4 (3 hydroxypheny1)-3,4-dimethy1-1-piperidinyllmethy11-2-methylpropy1)-1, 2,3,4-tetrahydro-3-isoquinolinecarboxamide as a novel potent and selective opioid x-receptor antagonist. J. Med. Chem. (2003) 46:3127–3137.
   PubMedGoogle Scholar
• ZIMMERMAN DM, NICKANDER R, HORNG JS, WONG DT: New structural concepts for structural antagonists defined in a 4-phenylpiperidine series. Nature (1978) 275: 332–334.
   PubMed Web of Science ®Google Scholar
• THOMAS JB, ATKINSON RN, NAMDEV N et al.: Discovery of an opioid x-receptor selective pure antagonist from a library of N-substituted 4f3-methyl-5- (3-hydroxyphenyl)morphans. J. Med. Chem. (2002) 45: 3524–3530.
   PubMed Web of Science ®Google Scholar
• XU W, HUANG L-F, BAUER L, BHARGAVA HN, DUNN WJ III: Synthesis and opiate receptor binding properties of 17-methy1-6,7-dehydro-3,14-dihydroxy-4,5a-epoxy-6,7:4',5'-pyrimidinomorphinans. Bioorg. Med. Chem. Lett. (1999) 9:3375–3380.
   PubMed Web of Science ®Google Scholar
• KO MCH, LEE H, SONG MS et al: Activation of x-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. ./. Pharmacol Exp. Ther. (2003) 305: 173–179.
   PubMed Web of Science ®Google Scholar
• KO MCH, SONG MS, EDWARDS T et al: The role of central [t opioid receptors in opioid-induced itch in primates. J. Pharmacol Exp. Ther. (2004) 310:169–176.
   PubMed Web of Science ®Google Scholar
• TOGASHI Y, UMEUCHI H, OKANO K et al: Antipruritic activity of the x-opioid receptor agonist, TRK-820. Eur..1. Pharmacol (2002) 435:259–264.
   PubMed Web of Science ®Google Scholar
• GHONIEM GM, SHAABAN AM, CLARKE MR: Irritable bladder syndrome in an animal model: a continuous monitoring study. Neurourol Urodyn. (1995) 14:657–665.
   PubMed Web of Science ®Google Scholar
• MAGUE SD, PLIAKAS AM, TODTENKOPF MS et al: Antidepressant-like effects of x-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol Exp. Ther. (2003) 305:323–330.
   PubMed Web of Science ®Google Scholar
• BARBER A, GOTTSCHLICH R: Novel developments with selective, non-peptidic x-opioid receptor agonists. Exp. Opin. Investig. Drugs (1997) 6:1351–1368.
   PubMedGoogle Scholar
• MACHELSKA H, PFLUGER M, WEBER W et al. Peripheral effects of the x-opioid agonist EMD-61753 on pain and inflammation in rats and humans. Pharmacol Exp. Ther. (1999) 290:354–361.
   PubMed Web of Science ®Google Scholar
• VANDERAH TW, SCHTEINGART CD, TROJNAR J et al: FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious lc opioid agonist with unprecedented selectivity. Pharmacol Exp. Ther. (2004) 310:326–333.
   PubMed Web of Science ®Google Scholar
• •A new peripherally selective KOR agonist that makes use of the normally problematic ability of peptides to enter the CNS.
   Google Scholar
• RIVIERE PJ: Peripheral x-opioid agonistsfor visceral pain. Br. J. Pharmacol (2004) 141:1331–1334.
   PubMed Web of Science ®Google Scholar
• EISENACH JC, CARPENTER R, CURRY R: Analgesia from a peripherally active x-opioid receptor agonist in patients with chronic pancreatitis. Pain (2003) 101:89–95.
   PubMed Web of Science ®Google Scholar
• MARTIN WR, GORODETZKY CW, McLANE TK: An experimental study in the treatment of narcotic addicts with cyclazocine. Chi'. Pharmacol Ther. (1966) 455–464.
   Google Scholar
• Buprenorphine. Combating Drug Abuse witha Unique Opioid. Cowan A, Lewis JW (Eds), Wiley-Liss, New York (1995):326.
   Google Scholar